Background Glucocorticoids have been widely used to treat patients with chronic obstructive pulmonary disease (COPD). Nevertheless, corticosteroid insensitivity is a major barrier to the effective treatment of COPD an...Background Glucocorticoids have been widely used to treat patients with chronic obstructive pulmonary disease (COPD). Nevertheless, corticosteroid insensitivity is a major barrier to the effective treatment of COPD and its mechanism remains unclear. This study aimed to evaluate the effect of cathelicidin LL-37 on corticosteroid insensitivity in COPD rat model, and to explore the involved mechanisms. Methods COPD model was established by exposing male Wistar rats to cigarette smoke combined with intratracheal instillation of lipopolysaccharide (LPS). Inhaled budesonide and LL-37 were consequently applied to COPD models separately or collectively to confirm the effects on inflammatory cytokines (tumor necrosis factor [TNF]-α and transforming growth factor [TGF]-β)by enzymelinked immunosorbent assay (ELISA) and lung tissue histopathological morphology. Expression of histone deacetylase-2 (HDAC2) and phosphorylation of Akt (p-AKT) in lung were also measured. Results Briefly, COPD model rats showed an increased basal release of inflammatory cytokines (lung TNF-α:45.7±6.1 vs. 20.1 ± 3.8pg/mL, P<0.01;serum TNF-α:8.9±1.2 vs. 6.7±0.5pg/mL, P = 0.01;lung TGF-β:122.4±20.8 vs. 81.9±10.8pg/mL, P<0.01;serum TGF-β:38.9±8.5 vs. 20.6±2.3 pg/mL, P<0.01) and COPD related lung tissue histopathological changes, as well as corticosteroid resistance molecular profile characterized by an increase in phosphoinositide 3-kinase (PI3K)/Akt (0.5±0.1 fold of control vs. 0.2±0.1 fold of control, P = 0.04) and a decrease in HDAC2 expression and activity (expression: 13.1 ±0.4 μmol/μg vs. 17.4± 1.1 μmol/μg, P<0.01;activity: 1.1 ±0.1 unit vs. 1.4±0.1 unit, P< 0.01), compared with control group. In addition, LL-37 enhanced the anti-inflammatory effect of budesonide in an additive manner. Treatment with combination of inhaled corticosteroids (ICS) and LL-37 led to a significant increase of HDAC2 expression and activity (expression: 15.7±0.4 μmol/μg vs. 14.1 ±0.9 μmol/μg, P<0.01;activity: 1.3±0.1 unit vs.1.0±0.1 unit,展开更多
目的观察参芪补肺汤对慢性阻塞性肺疾病(COPD)肺气虚证大鼠支气管平滑肌(ASM)中乙酰化组蛋白H4、组蛋白去乙酰化酶-2(HDAC2)和核因子-κB p65(NF-κB p65)表达的影响。方法取SD大鼠40只,随机分为正常组、模型组、参芪补肺汤组、氨茶碱组...目的观察参芪补肺汤对慢性阻塞性肺疾病(COPD)肺气虚证大鼠支气管平滑肌(ASM)中乙酰化组蛋白H4、组蛋白去乙酰化酶-2(HDAC2)和核因子-κB p65(NF-κB p65)表达的影响。方法取SD大鼠40只,随机分为正常组、模型组、参芪补肺汤组、氨茶碱组,每组10只。运用气管内注射脂多糖加烟熏28 d的方法建立COPD肺气虚证大鼠模型。光镜下观察肺组织的病理形态学变化,运用图像分析法测量小气道管壁和ASM的厚度,采用免疫组化和Western blot方法检测大鼠ASM中乙酰化组蛋白H4、HDAC2和NF-κB p65的蛋白表达,实时荧光定量PCR方法检测大鼠ASM组织中HDAC2 m RNA和NF-κB p65 m RNA的表达。结果与正常组比较,模型组大鼠气道管壁和ASM厚度明显增高(P<0.05);与模型组比较,参芪补肺汤组和氨茶碱组气道管壁和ASM厚度明显降低(P<0.05);参芪补肺汤组与氨茶碱组比较差异无统计学意义(P>0.05)。与正常组比较,模型组乙酰化组蛋白H4的蛋白表达、NF-κB p65 m RNA和蛋白的表达明显增高(P<0.05);HDAC2m RNA和蛋白的表达均明显降低(P<0.05);与模型组比较,参芪补肺汤组和氨茶碱组乙酰化组蛋白H4的蛋白表达、NF-κB p65 m RNA和蛋白的表达明显增高(P<0.05);HDAC2 m RNA和蛋白的表达明显降低(P<0.05)。参芪补肺汤组与氨茶碱组比较差异均无统计学意义(P>0.05)。结论参芪补肺汤可抑制COPD肺气虚证模型大鼠ASM增殖,其机制与其提高HDAC2的表达,使组蛋白H4去乙酰化,从而抑制NF-κB p65的表达有关。展开更多
基金National Natural Science Foundation of China (No.81300033).
文摘Background Glucocorticoids have been widely used to treat patients with chronic obstructive pulmonary disease (COPD). Nevertheless, corticosteroid insensitivity is a major barrier to the effective treatment of COPD and its mechanism remains unclear. This study aimed to evaluate the effect of cathelicidin LL-37 on corticosteroid insensitivity in COPD rat model, and to explore the involved mechanisms. Methods COPD model was established by exposing male Wistar rats to cigarette smoke combined with intratracheal instillation of lipopolysaccharide (LPS). Inhaled budesonide and LL-37 were consequently applied to COPD models separately or collectively to confirm the effects on inflammatory cytokines (tumor necrosis factor [TNF]-α and transforming growth factor [TGF]-β)by enzymelinked immunosorbent assay (ELISA) and lung tissue histopathological morphology. Expression of histone deacetylase-2 (HDAC2) and phosphorylation of Akt (p-AKT) in lung were also measured. Results Briefly, COPD model rats showed an increased basal release of inflammatory cytokines (lung TNF-α:45.7±6.1 vs. 20.1 ± 3.8pg/mL, P<0.01;serum TNF-α:8.9±1.2 vs. 6.7±0.5pg/mL, P = 0.01;lung TGF-β:122.4±20.8 vs. 81.9±10.8pg/mL, P<0.01;serum TGF-β:38.9±8.5 vs. 20.6±2.3 pg/mL, P<0.01) and COPD related lung tissue histopathological changes, as well as corticosteroid resistance molecular profile characterized by an increase in phosphoinositide 3-kinase (PI3K)/Akt (0.5±0.1 fold of control vs. 0.2±0.1 fold of control, P = 0.04) and a decrease in HDAC2 expression and activity (expression: 13.1 ±0.4 μmol/μg vs. 17.4± 1.1 μmol/μg, P<0.01;activity: 1.1 ±0.1 unit vs. 1.4±0.1 unit, P< 0.01), compared with control group. In addition, LL-37 enhanced the anti-inflammatory effect of budesonide in an additive manner. Treatment with combination of inhaled corticosteroids (ICS) and LL-37 led to a significant increase of HDAC2 expression and activity (expression: 15.7±0.4 μmol/μg vs. 14.1 ±0.9 μmol/μg, P<0.01;activity: 1.3±0.1 unit vs.1.0±0.1 unit,
文摘目的观察参芪补肺汤对慢性阻塞性肺疾病(COPD)肺气虚证大鼠支气管平滑肌(ASM)中乙酰化组蛋白H4、组蛋白去乙酰化酶-2(HDAC2)和核因子-κB p65(NF-κB p65)表达的影响。方法取SD大鼠40只,随机分为正常组、模型组、参芪补肺汤组、氨茶碱组,每组10只。运用气管内注射脂多糖加烟熏28 d的方法建立COPD肺气虚证大鼠模型。光镜下观察肺组织的病理形态学变化,运用图像分析法测量小气道管壁和ASM的厚度,采用免疫组化和Western blot方法检测大鼠ASM中乙酰化组蛋白H4、HDAC2和NF-κB p65的蛋白表达,实时荧光定量PCR方法检测大鼠ASM组织中HDAC2 m RNA和NF-κB p65 m RNA的表达。结果与正常组比较,模型组大鼠气道管壁和ASM厚度明显增高(P<0.05);与模型组比较,参芪补肺汤组和氨茶碱组气道管壁和ASM厚度明显降低(P<0.05);参芪补肺汤组与氨茶碱组比较差异无统计学意义(P>0.05)。与正常组比较,模型组乙酰化组蛋白H4的蛋白表达、NF-κB p65 m RNA和蛋白的表达明显增高(P<0.05);HDAC2m RNA和蛋白的表达均明显降低(P<0.05);与模型组比较,参芪补肺汤组和氨茶碱组乙酰化组蛋白H4的蛋白表达、NF-κB p65 m RNA和蛋白的表达明显增高(P<0.05);HDAC2 m RNA和蛋白的表达明显降低(P<0.05)。参芪补肺汤组与氨茶碱组比较差异均无统计学意义(P>0.05)。结论参芪补肺汤可抑制COPD肺气虚证模型大鼠ASM增殖,其机制与其提高HDAC2的表达,使组蛋白H4去乙酰化,从而抑制NF-κB p65的表达有关。
